The activation of PPARγ is a key mechanism for ameliorating hyperglycemia, and IR and PPARγ agonists, such as PIO, increase insulin sensitivity and ameliorate hyperglycemia, dyslipidemia, OS, and inflammation (Tontonoz and Spiegelman, 2008). The gene discussed is INS; the disease is metabolic syndrome.